About amp biosimilars
amp biosimilars AG develops high-quality biosimilars for the growing demand of the global therapeutics markets and is one of the most innovative and dynamic biosimilar companies in Europe. Headquartered in Hamburg, Germany, the company is managed by a team of leading industry experts. By developing a wide range of biosimilars, the company aims to provide patients worldwide with access to life-improving and life-saving therapies. Combining a research platform of state-of-the-art analytics, process technology and clinical expertise with regulatory know-how, amp biosimilars AG is one of the leading companies in biosimilar development and commercialization. Due to an international network with leading pharmaceutical companies, amp biosimilars AG also has direct access to the markets with the most dynamic growth worldwide. With this approach, amp biosimilars has a key position in one of the fastest growing markets in the life sciences sector for the coming years. amp biosimilars AG has been listed on the Munich Stock Exchange since April 1, 2015.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Industry : Biotechnology
